DOCSLIB.ORG

By Forging New Relationships and Finding Novel

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
By Forging New Relationships and Finding Novel By forging new relationships and finding novel uses for existing technologies, this year’s top companies are employing creative ways to advance their science. BY HANNAH WATERS ike the reeds of an old Aesop fable, the companies that deals potentially worth more than $800 million with pharmaceu- topped our 2011 Best Places to Work in Industry survey tical giants GlaxoSmithKline and Eisai to develop epigenetics- L are bending—but not breaking—under the strain of con- targeted therapies for cancer and other diseases. “It’s a good sign tinued economic adversity. With funding agencies still awarding for our company’s stability in the near term,” says Epizyme re- grants only to the cream of the crop and 2009 stimulus funds search associate Christina Allain. expected to run dry as soon as next year, companies are working Other top companies are collaborating with a different type hard to find new funding sources that will allow them to survive of partner altogether—academia. Conversant Bio, a Huntsville, despite the still-depressed economy. Alabama–based biotech that offers patient-sample and cell-based Taking advantage of the growing personal-genomics boom, for assays, formed relationships with labs at Stanford University to example, DNA Genotek, the survey’s #8 company, expanded the share samples, equipment, and information. And in Fargo, North market for its saliva-based DNA collection kit from population ge- Dakota, 3rd-ranked Aldevron is participating in a state-funded neticists in the field to consumers in their homes by licensing its project to build a science city, involving collaborations between wares to genetic-testing companies. The recent uptick in the use North Dakota State University labs and local research companies. of personalized genetic tests has boosted DNA Genotek’s income, “There’s a really neat synergy that’s forming here,” says Aldevron’s OM C which the company puts right back into basic research. “Personal director of business development Michael Jablon. O. T genomics just became yet another market that we’re playing into,” Read on to learn more about the strengths and weaknesses KPHO says DNA Genotek product development manager Rafal Iwasiow. of this year’s top-ranking companies, how multinational compa- C O T New collaborations were also common among this year’s top nies are using their diversity to their advantage, and the different S I companies. Epizyme, the survey’s #1 company, which specializes ways companies are creatively utilizing state and federal funding 4X6 / in developing inhibitors for epigenetic enzymes, recently signed to help their researchers succeed. CREDIT LINE 05.2011 | THE SCIENTIst | the-scientist.com 43 BEST PLACES TO WORK TOP 40 COMPANIES #1-20 RANK RANK NO. OF 2011 2010 COMPANY SIZE EMPLOYEES StrENGTHS WEAKNESSES Integrity Remuneration and Benefits Epizyme, Cambridge, MA Small < 50 1 - Communications Training and Development Job Satisfaction Remuneration and Benefits Conversant Bio, Huntsville, AL Small < 50 2 - Management Training and Development Communications Training and Development Aldevron, Fargo, ND Small 50 - 100 3 - Remuneration and Benefits Research Environment Training and Development Communications Millennium Pharmaceuticals, Cambridge, MA Small 1,000+ 4 - Remuneration and Benefits Integrity Policies and Practices Research Environment Acorda Therapeutics, Hawthorne, NY Small 100 - 500 5 - Training and Development Communications Research Environment Training and Development Vitae Pharmaceuticals, Fort Washington, PA Small 50 6 - Management Remuneration and Benefits Remuneration and Benefits Job Satisfaction - Celldex Therapeutics, Needham, MA Small 100 7 Training and Development Integrity Job Satisfaction Remuneration and Benefits DNA Genotek, Kanata, Ontario Small 50 - 100 8 - Integrity Training and Development Job Satisfaction Training and Development Wyatt Technology, Santa Barbara, CA Small 100 - 500 9 2 Management Research Environment Training and Development Research Environment DuPont, Wilmington, DE Large 6,000 10 - Job Satisfaction Management Remuneration and Benefits Job Satisfaction Vertex Pharmaceuticals, Cambridge, MA Small 1,500+ 11 - Policies and Practices Communications Training and Development Research Environment Pioneer Hi-Bred: A DuPont Business, Johnston, IA Large 10,000+ 12 8 Integrity Remuneration and Benefits Training and Development Research Environment Dow AgroSciences, Indianapolis, IN Large 5,000+ 13 7 Remuneration and Benefits Communications Research Environment Remuneration and Benefits Integrated DNA Technologies, Coralville, IA Small 500 - 1,000 14 9 Communications Training and Development Remuneration and Benefits Management Monsanto, St. Louis, MO Large 20,000 15 5 Training and Development Research Environment Remuneration and Benefits Job Satisfaction Amgen, Thousand Oaks, CA Large 17,000 16 16 Integrity Training and Development Training and Development Integrity Alnyalm Pharmaceuticals, Cambridge, MA Small * 17 12 Communications Management Remuneration and Benefits Communications Novartis, Basel, Switzerland Large 115,000+ 18 17 Training and Development Policies and Practices Job Satisfaction Research Environment Promega Corporation, Madison, WI Small 1,000+ 19 - Training and Development Remuneration and Benefits Job Satisfaction Remuneration and Benefits Cancer Genetics Inc., Rutherford, NJ Small 50 20 - Communications Research Environment Epigenetic Endeavors at Epizyme Epizyme, the #1 company on this year’s overall Based in Cambridge, Massachusetts, the company re- list, has grown exponentially since its founding in searches the epigenetics of cancer and develops drugs to mod- 2007—from just two employees to its current R&D ify variations in DNA methylation. The company recently iden- staff of 26. In the last year, the company identified tified how normal and mutant histone methyltransferase EZH2 two novel mechanisms linked to cancer, inked partnerships with work together to regulate growth in B-cell lymphomas, and de- two major pharmaceutical companies, and signed a lease on a larger veloped a small-molecule inhibitor for another methyltransfer- office. The growth is “a tremendous validation of us as a company ase, DOT1L, which is able to selectively kill mixed-lineage leu- and how we’re executing things,” says medicinal chemist Ed Olhava. kemia cells in vitro. 44 FACULTY OF 1000 | f1000.com #21-40 RANK RANK NO. OF 2011 2010 COMPANY SIZE EMPLOYEES StrENGTHS WEAKNESSES Communications Integrity ArQule, Woburn, MA Small 100 - 500 21 - Policies and Practices Management Job Satisfaction Training and Development - Tengion, East Norriton, PA Small 50 - 100 22 Communications Remuneration and Benefits Management Remuneration and Benefits Targacept, Winston-Salem, NC Small 100 - 500 23 22 Job Satisfaction Training and Development Remuneration and Benefits Integrity Otsuka Maryland Medicinal Laboratories, Rockville, MD Small 100 - 500 24 4 Research Environment Communications Research Environment Remuneration and Benefits Lexicon Pharmaceuticals, The Woodlands, TX Small 100 - 500 25 21 Management Training and Development Integrity Training and Development Agilent Technologies, Santa Clara, CA Large 15,000+ 26 - Research Environment Policies and Practices Training and Development Research Environment Bayer Corp, Leverkusen, Germany Large 110,000+ 27 - Remuneration and Benefits Communications Remuneration and Benefits Training and Development Abbott Laboratories, Abbott Park, IL Large 90,000 28 10 Management Policies and Practices Training and Development Communications Pfizer, New York, NY Large 110,000 29 18 Remuneration and Benefits Integrity Policies and Practices Research Environment Genzyme, Cambridge, MA Large 10,000 30 - Remuneration and Benefits Management Remuneration and Benefits Job Satisfaction GlaxoSmithKline, Middlesex, UK Large 99,000 31 29 Integrity Management Communications Integrity Emergent Biosolutions, Rockville, MD Small 100 - 500 32 - Training and Development Research Environment Job Satisfaction Research Environment Syngenta Biotechnology, Basel, Switzerland Large 25,000 33 - Training and Development Management Job Satisfaction Communications Boehringer Ingelheim, Ingelheim am Rhein, Germany Large 40,000+ 34 - Management Remuneration and Benefits Training and Development Remuneration and Benefits Regeneron Pharmaceuticals, Tarrytown, NY Small 1,500 35 23 Research Environment Job Satisfaction Remuneration and Benefits Training and Development AstraZeneca, London, UK Large 63,000 36 20 Management Research Environment Policies and Practices Training and Development Asterand, Detroit, MI Small 100 37 32 Job Satisfaction Management Remuneration and Benefits Job Satisfaction Merck KGaA, Darmstadt, Germany Large 40,000+ 38 24 Training and Development Research Environment Remuneration and Benefits Communications Merck & Co., Whitehouse Station, NJ Large 94,000 39 25 Policies and Practices Training and Development Research Environment Training and Development Bristol-Myers Squibb, New York, NY Large 27,000 40 - Job Satisfaction Management Small companies have < 4,000 employees * Declined to provide information Epizyme’s research has attracted the attention of pharmaceu- come. “It’s a great morale boost,” says Christina Allain, who de- tical giant GlaxoSmithKline, which announced its partnership velops cell-based assays for the company—“a pat on the back.” with Epizyme in January, providing the company with up to $650 Despite its growth, the company has stayed in the same, small million to search for new epigenetic drugs.
Load more

Recommended publications
  • United States Court of Appeals for The
    Case 14-4353, Document 100-1, 05/16/2016, 1772362, Page1 of 37 14‐4353‐cv Apotex Inc., et al., v. Acorda Therapeutics, Inc. UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT August Term, 2015 (Argued: November 12, 2015 Decided: May 16, 2016) Docket No. 14‐4353‐cv ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐x APOTEX INC., et al., Plaintiffs‐Appellants, ‐ v.‐ ACORDA THERAPEUTICS, INC., Defendant‐Appellee. ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐x Before: JACOBS, LIVINGSTON and DRONEY, Circuit Judges. This appeal concerns two distinct questions: the circumstances under which the filing of a citizen petition with the Food and Drug Administration provides grounds for an antitrust claim, and the scope of false advertising Case 14-4353, Document 100-1, 05/16/2016, 1772362, Page2 of 37 liability under the Lanham Act. Plaintiffs Apotex Incorporated and Apotex Corporation appeal from the judgment of the United States District Court for the Southern District of New York (Swain, J.) that granted defendant Acorda Therapeutics, Inc.’s motion to dismiss plaintiffs’ Sherman Act claim and that granted summary judgment in favor of defendant on the Lanham Act claims (Torres, J.). Because each of these conclusions was sound, we affirm. KEITH D. PARR (with Joseph N. Froehlich, Scott B. Feder, Hugh S. Balsam, James T. Peterka, and Andy J. Miller on the brief), Locke Lord LLP, Chicago, Illinois, for Appellants Apotex Incorporated & Apotex Corporation. JOHN W. NIELDS, JR. (with Jason C. Raofield and Colin P. Watson on the brief), Covington & Burling LLP, Washington, D.C. for Appellee Acorda Therapeutics, Inc. DENNIS JACOBS, Circuit Judge: The parties are rival manufacturers of tizanidine, a drug for treating spasticity.
    [Show full text]
  • Companies in Attendance
    COMPANIES IN ATTENDANCE Abbott Diabetes Care Archbow Consulting LLC Business One Technologies Abbott Laboratories ARKRAY USA BusinessOneTech AbbVie Armory Hill Advocates, LLC CastiaRX ACADIA Artia Solutions Catalyst Acaria Health Asembia Celgene Accredo Assertio Therapeutics Celltrion Acer Therapeutics AssistRx Center for Creative Leadership Acorda Therapeutics Astellas Pharma US Inc. Cigna Actelion AstraZeneca Cigna Specialty Pharmacy AdhereTech Athenex Oncology Circassia Advantage Point Solutions Avanir Coeus Consulting Group Aerie Pharmaceuticals Avella Coherus Biosciences AGIOS AveXis Collaborative Associates LLC Aimmune Theraputics Bank of America Collegium Akcea Therapeutics Bausch Health Corsica Life Sciences Akebia Therapeutics Bayer U.S. CoverMyMeds Alder BioPharmaceuticals Becton Dickinson Creehan & Company, Inc., an Inovalon Company Alexion Biofrontera CSL Behring Alkermes Biogen Curant Health Allergan Biohaven CVS Health Almirall BioMarin D2 Consulting Alnylam BioMatrix Specialty Pharmacy Daiichi Sankyo Amarin BioPlus Specialty Pharmacy DBV Technologies Amber Pharmacy Bioventus Deloitte Consulting LLP AmerisourceBergen Blue Cross Blue Shield Association Dendreon Amgen Blue Fin Group Dermira Amicus Therapeutics bluebird bio Dexcom Amneal Boehringer Ingelheim Diplomat Pharmacy Anthem Boston Biomedical Dova Applied Policy Bowler and Company Decision Resources Group Aquestive Therapeutics Braeburn Eisai Arbor Pharmaceuticals Bristol-Myers Squibb 1 electroCore Indivior Merz Pharmaceuticals EMD Serono Inside Rx Milliman Encore Dermatology,
    [Show full text]
  • FDA Listing of Authorized Generics As of July 1, 2021
    FDA Listing of Authorized Generics as of July 1, 2021 Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs). Because the annual reports seldom indicate the date an AG initially entered the market, the column headed “Date Authorized Generic Entered Market” reflects the period covered by the annual report in which the AG was first reported. Subsequent marketing dates by the same firm or other firms are not included in this listing. As noted, in many cases FDA does not have information on whether the AG is still marketed and, if not still marketed, the date marketing ceased. Although attempts have been made to ensure that this list is as accurate as possible, given the volume of d ata reviewed and the possibility of database limitations or errors, users of this list are cautioned to independently verify the information on the list. We welcome comments on and suggested changes (e.g., additions and deletions) to the list, but the list may include only information that is included in an annual report. Please send suggested changes to the list, along with any supporting documentation to: [email protected] A B C D E F G H I J K L M N O P Q R S T U V X Y Z NDA Applicant Date Authorized Generic Proprietary Name Dosage Form Strength Name Entered the Market 1 ACANYA Gel 1.2% / 2.5% Bausch Health 07/2018 Americas, Inc.
    [Show full text]
  • Fidelity® Nasdaq Composite Index® Fund
    Fidelity® Nasdaq Composite Index® Fund Semi-Annual Report May 31, 2021 Contents Note to Shareholders 3 Investment Summary 4 Schedule of Investments 6 Financial Statements 85 Notes to Financial 89 Statements Shareholder Expense 97 Example Board Approval of 98 Investment Advisory Contracts and Management Fees Liquidity Risk 106 Management Program To view a fund’s proxy voting guidelines and proxy voting record for the 12-month period ended June 30, visit http://www.fidelity.com/proxyvotingresults or visit the Securities and Exchange Commission’s (SEC) web site at http://www.sec.gov. You may also call 1-800-544-8544 to request a free copy of the proxy voting guidelines. Nasdaq®, OMX®, NASDAQ OMX®, Nasdaq Composite®, and The Nasdaq Stock Market®, Inc. are registered trademarks of The NASDAQ OMXGroup, Inc. (which with its Affiliates are the Corporations) and are licensed for use by Fidelity. The product has not been passed on by the Corporations as to its legality or suitability. The product is not issued, endorsed or sold by the Corporations. The Corporations make no warranties and bear no liability with respect to shares of the product. Standard & Poor’s, S&P and S&P 500 are registered service marks of The McGraw-Hill Companies, Inc. and have been licensed for use by Fidelity Distributors Corporation. Other third-party marks appearing herein are the property of their respective owners. All other marks appearing herein are registered or unregistered trademarks or service marks of FMR LLC or an affiliated company. © 2021 FMR LLC. All rights reserved. This report and the financial statements contained herein are submitted for the general information of the shareholders of the Fund.
    [Show full text]
  • Tuesday, November 29 Track One Villard, 2Nd Floor Track Two
    Tuesday, Track One Track Two Track Three Track Four Track Five Track Six Track Seven November 29 Villard, 2nd Floor Spellman, 5th Floor Holmes 1, 4th Floor Holmes 2, 4th Floor Hubbard 1, 5th Floor Kennedy 1, 4th Floor Kennedy 2, 4th Floor Public & Private Track Private Track Registration - Villard Foyer, 2nd Floor 7:30 Continental Breakfast - Reid Salon, 2nd Floor 7:30 DentalPlans.com, Inc. SYMIC BIO, INC. Luminex Corporation Insmed Incorporated AngioDynamics Inc. Vascular Biogenics Ltd. 7:30-7:55 ConforMIS, Inc. (CFMS) (LMNX) (INSM) (ANGO) (VBLT) 7:50 OticPharma, Ltd. Accera, Inc. Gilead Sciences, Inc. Medidata Solutions, Inc. Horizon Pharma plc NxStage Medical, Inc. Acorda Therapeutics, UDG Healthcare plc 8:00-8:25 8:10 Availity, LLC (GILD) (MDSO) (HZNP) (NXTM) Inc. (ACOR) (UDG LN) MiMedx Group, Inc. 8:30 VisionGate, Inc. Boston Scientific Masimo Corporation COMPANY TO BE (MDXG) 8:30-8:55 Akorn, Inc. (AKRX) Teladoc, Inc. (TDOC) Corporation (BSX) (MASI) ANNOUNCED (JS) Anika Therapeutics Inc. 8:50 Benvenue Medical, Inc. (ANIK) Supernus Zimmer Biomet Henry Schein, Inc. Benefitfocus, Inc. Stealth BioTherapeutics 9:00-9:25 Pharmaceuticals, Inc. Ignyta, Inc. (RXDX) 9:10 EarLens Corporation Holdings, Inc. (ZBH) (HSIC) (BNFT) Incorporated (SUPN) Schedule for Tuesday, November 29, 2016 - Page 1 of 10 Schedule as of November 18, 2016. Schedule is subject to change. Tuesday, Track One Track Two Track Three Track Four Track Five Track Six Track Seven November 29 Villard, 2nd Floor Spellman, 5th Floor Holmes 1, 4th Floor Holmes 2, 4th Floor Hubbard 1, 5th Floor Kennedy 1, 4th Floor Kennedy 2, 4th Floor ProMetic Life Sciences Adamas 9:30 Graybug Vision, Inc.
    [Show full text]
  • Deal Point Data Rankings Include Mergers & Acquisitions With
    Public Mergers & Acquisitions (US & Non-US Targets) Deal Point Data rankings include mergers & acquisitions with a US or non-US public target and at least one SEC filer participant. Top Target and Acquirer M&A Financial Advisers Created: 10/Aug/2016 www.dealpointdata.com/ranking Search Criteria Target industry: Healthcare Include only highest bid in pending competing deals. Exclude withdrawn deals. Equity Value Equity Value Equity Value % Rank Rank Advice or Opinion $m $m Change Deal Count Deal Count 2016 2015 Financial Adviser 2016 2015 2015 to 2016 2016 2015 1 7 Evercore Partners 44,102 32,317 36 5 2 2 10 Guggenheim Partners 33,859 18,844 80 5 4 3 15 Bank of America Merrill Lynch 26,599 3,442 673 3 1 4 1 JPMorgan 23,628 68,999 -66 9 10 5 5 Centerview Partners LLC 13,542 42,693 -68 4 5 6 21 Rothschild Inc. 7,160 1,364 425 1 1 Skandinaviska Enskilda Banken 6 - AB 7,160 - - 1 0 8 8 Barclays 5,191 30,919 -83 2 1 9 4 Citigroup Inc. 4,767 46,899 -90 2 7 10 - Perella Weinberg Partners 1,891 - - 4 0 11 19 MTS Health Partners, L.P. 1,634 1,398 17 2 1 12 19 Credit Suisse 1,432 1,398 2 1 1 13 - RBC Capital Markets 1,285 - - 1 0 14 3 Goldman, Sachs & Co. 1,082 53,432 -98 1 9 15 2 Morgan Stanley 714 66,510 -99 1 4 16 - Duff & Phelps, LLC 391 - - 1 0 17 8 Lazard 349 30,919 -99 1 4 18 30 Roth Capital Partners, LLC 264 46 474 1 1 Stifel, Nicolaus & Company, 19 - Incorporated 141 - - 1 0 20 12 Jefferies LLC 85 6,750 -99 1 3 21 - PJT Partners 75 - - 1 0 22 - KPMG 60 - - 1 0 23 - Greenhill and Co 43 - - 1 0 24 - Oppenheimer & Co.
    [Show full text]
  • In the United States District Court for the District Of
    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC;, et al., ) ) Plaintiffs, ) ) v. ) Civ. No. 15-960-SLR ) MYLAN INC., et al., ) ) Defendants. ) ) Jack B. Blumenfeld, Esquire and Maryellen Noreika, Esquire of Morris Nichols, Arsht & Tunnell LLP, Wilmington, Delaware. Counsel for Plaintiffs. David E. Moore, Esquire, Bindu A. Palapura, Esquire, and Stephanie E. O'Byrne, Esquire of Potter Anderson & Corroon LLP, Wilmington, Delaware. Counsel for Defendants. Of Counsel: Robert L. Florence, Esquire, Karen L. Carroll, Esquire, and Micheal L. Binns, Esquire, Melanie Black Dubis, Esquire of Parker, Poe, Adams & Bernstein LLP. MEMORANDUM OPINION Dated: August \} , 2016 Wilmington, Delaware ROBINSON~ I. INTRODUCTION On October 22, 2015, Pfizer Inc., Wyeth LLC, Pfizer Pharmaceuticals LLC, PF PRISM C.V., ~nd Pfizer Manufacturing Holdings LLC, (collectively "plaintiffs") filed a complaint alleging infringement of three patents related to its injectable antibiotic product TYGACIL ® ("Tygacil") against defendants Mylan Inc., Mylan N.V., Mylan Laboratories Ltd. ("MLL"), and Mylan Pharmaceuticals ("MPI") (collectively "defendants"). (D.I. 1) Presently before the court is defendants' motion to dismiss for lack of personal jurisdiction and improper venue. (D.I. 6) Defendants Mylan Inc., Mylan N.V., and MPI have also filed a motion dismiss for failure to state a claim. (Id.) The court has jurisdiction over this matter pursuant to 28 U.S.C. §§ 1331 and 1338(a). II. BACKGROUND A. The parties Plaintiff Pfizer Inc. is a corporation organized and existing under the laws of the State of Delaware with a principal place of business in New York, New York. (D.I. 1 at~ 2) Plaintiff Wyeth LLC is a Delaware limited liability company with a principal place of business in New York, New York.
    [Show full text]
  • 05/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 04:25:50 Report Id 2794D052 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 05/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 04:25:50 REPORT ID 2794D052 PAGE: 01 ALPHA COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 07/01/2016 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 68782 (OSI) EYETECH 55513 AMGEN USA 00074 ABBOTT LABORATORIES 58406 AMGEN/IMMUNEX 68817 ABRAXIS BIOSCIENCE, LLC 53746 AMNEAL PHARMACEUTICALS 16729 ACCORD HEALTHCARE INCORPORATED 65162 AMNEAL PHARMACEUTICALS LLC 42192 ACELLA PHARMACEUTICALS, LLC 69238 AMNEAL PHARMACEUTICALS, LLC 10144 ACORDA THERAPEUTICS, INC. 53150 AMNEAL-AGILA, LLC 00472 ACTAVIS 00548 AMPHASTAR PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 69918 AMRING PHARMACEUTICALS, INC. 45963 ACTAVIS INC. 66780 AMYLIN PHARMACEUTICALS, INC. 46987 ACTAVIS KADIAN LLC 55724 ANACOR PHARMACEUTICALS 49687 ACTAVIS KADIAN LLC 10370 ANCHEN PHARMACEUTICALS, INC. 14550 ACTAVIS PHARMA MFGING PRIVATE LIMITED 43595 ANGELINI PHARMA, INC. 61874 ACTAVIS PHARMA, INC. 62559 ANIP ACQUISITION COMPANY 67767 ACTAVIS SOUTH ATLANTIC 54436 ANTARES PHARMA, INC. 66215 ACTELION PHARMACEUTICALS U.S., INC. 52609 APO-PHARMA USA, INC. 52244 ACTIENT PHARMACEUTICALS 60505 APOTEX CORP. 75989 ACTON PHARMACEUTICALS 63323 APP PHARMACEUTICALS, LLC. 69547 ADAPT PHARMA INC. 43485 APRECIA PHARMACEUTICALS COMPANY 76431 AEGERION PHARMACEUTICALS, INC. 42865 APTALIS PHARMA US, INC 50102 AFAXYS, INC. 58914 APTALIS PHARMA US, INC. 10572 AFFORDABLE PHARMACEUTICALS, LLC 13310 AR SCIENTIFIC, INC. 27241 AJANTA PHARMA LIMITED 08221 ARBOR PHARM IRELAND LIMITED 17478 AKORN INC 60631 ARBOR PHARMACEUTICALS IRELAND LIMITED 24090 AKRIMAX PHARMACEUTICALS LLC 24338 ARBOR PHARMACEUTICALS, INC. 68220 ALAVEN PHARMACEUTICAL, LLC 59923 AREVA PHARMACEUTICALS 00065 ALCON LABORATORIES, INC. 76189 ARIAD PHARMACEUTICALS, INC. 00998 ALCON LABORATORIES, INC. 24486 ARISTOS PHARMACEUTICALS, INC.
    [Show full text]
  • Rebateable Manufacturers
    Rebateable Labelers – July 2021 Manufacturers are responsible for updating their eligible drugs and pricing with CMS. Montana Healthcare Programs will not pay for an NDC not updated with CMS. Note: Some manufacturers on this list may have some NDCs that are covered and others that are not. Manufacturer ID Manufacturer Name 00002 ELI LILLY AND COMPANY 00003 E.R. SQUIBB & SONS, LLC. 00004 HOFFMANN-LA ROCHE 00006 MERCK & CO., INC. 00007 GLAXOSMITHKLINE 00008 WYETH PHARMACEUTICALS LLC, 00009 PHARMACIA AND UPJOHN COMPANY LLC 00013 PFIZER LABORATORIES DIV PFIZER INC 00015 MEAD JOHNSON AND COMPANY 00023 ALLERGAN INC 00024 SANOFI-AVENTIS, US LLC 00025 PFIZER LABORATORIES DIV PFIZER INC 00026 BAYER HEALTHCARE LLC 00032 ABBVIE INC. 00037 MEDA PHARMACEUTICALS, INC. 00039 SANOFI-AVENTIS, US LLC 00046 WYETH PHARMACEUTICALS INC. 00049 ROERIG 00051 ABBVIE INC 00052 ORGANON USA INC. 00053 CSL BEHRING L.L.C. 00054 HIKMA PHARMACEUTICAL USA, INC. 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00065 ALCON LABORATORIES, INC. 00068 AVENTIS PHARMACEUTICALS 00069 PFIZER LABORATORIES DIV PFIZER INC 00071 PARKE-DAVIS DIV OF PFIZER 00074 ABBVIE INC 00075 AVENTIS PHARMACEUTICALS, INC. 00078 NOVARTIS 00085 SCHERING CORPORATION 00087 BRISTOL-MYERS SQUIBB COMPANY 00088 AVENTIS PHARMACEUTICALS 00093 TEVA PHARMACEUTICALS USA, INC. 00095 BAUSCH HEALTH US, LLC Page 1 of 19 Manufacturer ID Manufacturer Name 00096 PERSON & COVEY, INC. 00113 L. PERRIGO COMPANY 00115 IMPAX GENERICS 00116 XTTRIUM LABORATORIES, INC. 00121 PHARMACEUTICAL ASSOCIATES, INC. 00131 UCB, INC. 00132 C B FLEET COMPANY INC 00143 HIKMA PHARMACEUTICAL USA, INC. 00145 STIEFEL LABORATORIES, INC, 00168 E FOUGERA AND CO. 00169 NOVO NORDISK, INC. 00172 TEVA PHARMACEUTICALS USA, INC 00173 GLAXOSMITHKLINE 00178 MISSION PHARMACAL COMPANY 00185 EON LABS, INC.
    [Show full text]
  • Appendix A: Overview of Selected Collaborations 1
    Appendix A: Overview of Selected Collaborations 1 Appendix A: Overview of Selected Collaborations The following appendix provides an overview of selected biopharmaceutical collaborations to advance efforts focused in the following areas: Research & Development, Public Health & Improving Patient Outcomes, Manufacturing & Distribution, Improving Access. Partnerships were grouped together based on a singular, or in some cases, overlapping focus area. The selected examples below, provide a brief overview of the collaboration’s purpose, partners, approach used to generate results and any successes yielding from the group’s efforts. R&D 3 Antimicrobial Resistance (AMR) Action Fund ____________________________________________________________________ 3 Alzheimer's Disease Neuroimaging Initiative (ADNI) _______________________________________________________________ 3 AstraZeneca’s Open Innovation _______________________________________________________________________________ 4 Lung Cancer Master Protocol (Lung-MAP) ______________________________________________________________________ 7 Multiple Sclerosis Partnership ________________________________________________________________________________ 7 Northeast ALS Consortium __________________________________________________________________________________ 8 One Brave Idea ___________________________________________________________________________________________ 8 Parkinson’s Disease Education Consortium (PDEC) _______________________________________________________________ 9 Rare Disease Cures
    [Show full text]
  • ACORDA THERAPEUTICS, INC. and ALKERMES PHARMA IRELAND LIMITED, Plaintiffs, V
    Page 1 ACORDA THERAPEUTICS, INC. and ALKERMES PHARMA IRELAND LIMITED, Plaintiffs, v. MYLAN PHARMACEUTICALS INC. and MYLAN INC., Defendants. Civil Action No. 14-935-LPS UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE 2015 U.S. Dist. LEXIS 4056 January 14, 2015, Decided January 14, 2015, Filed COUNSEL: For Plaintiffs: Jack B. Blumenfeld and have moved to dismiss the complaint filed against them Maryellen Noreika, MORRIS, NICHOLS, ARSHT & by Plaintiffs Acorda Therapeutics, Inc. ("Acorda") and TUNNELL, LLP, Wilmington, DE; Aaron Stiefel, Daniel Alkermes Pharma Ireland Limited ("Alkermes" and, P. DiNapoli, Benjamin C. Hsing, and Soumitra Deka, together with Acorda, "Plaintiffs"). (D.I. 10) Defendants KAYE SCHOLER, LLP, New York, NY; Sylvia M. bring their motion pursuant to Federal Rule of Civil Becker [*1] , KAYE SCHOLER, LLP, Washington, DC; Procedure 12(b)(2), asserting a lack of personal Anthony Michael, ACORDA THERAPEUTICS, INC., jurisdiction. Specifically, Mylan contends that the Ardsley, NY. Supreme Court's recent decision [*2] in Daimler AG v. Bauman, 134 S. Ct. 746, 187 L. Ed. 2d 624 (2014), has For Defendants: Mary B. Matterer and Richard K. resulted in the District of Delaware lacking general Herrmann, MORRIS JAMES, LLP, Wilmington, DE; jurisdiction over Mylan in this (and likely all)1 Timothy H. Kratz, George J. Barry III, Karen L. Carroll, Abbreviated New Drug Application ("ANDA") lawsuits. and Brie L.B. Buchanan, MCGUIREWOODS, LLP, Mylan further contends that its relationship with Atlanta, GA; Cedric C.Y. Tan, MCGUIREWOODS, Delaware and with this litigation does not support the LLP, Washington, DC. exercise of specific jurisdiction. JUDGES: Leonard P.
    [Show full text]
  • In the United States District Court for the District of Delaware
    Case 1:16-cv-00192-UNA Document 1 Filed 03/25/16 Page 1 of 11 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE GILEAD SCIENCES, INC., ) ) Plaintiff, ) ) v. ) C.A. No. ) MYLAN PHARMACEUTICALS INC., ) ) Defendant. ) COMPLAINT FOR PATENT INFRINGEMENT Plaintiff Gilead Sciences, Inc. (“Plaintiff”) brings this Complaint for patent infringement against Defendant Mylan Pharmaceuticals Inc. (“Mylan”) and alleges as follows: NATURE OF THE ACTION 1. This is a civil action for patent infringement by Mylan of U.S. Patent No. 8,148,374 (“the ’374 Patent”), arising under the patent laws of the United States, 35 U.S.C. § 100 et seq., and, more particularly 35 U.S.C. §§ 271(a), (b), (c), (e), and 281. This action relates to the Abbreviated New Drug Application (“ANDA”) No. 208982, filed by Mylan with the United States Food and Drug Administration (“FDA”) for approval to market generic versions of Gilead Sciences, Inc.’s Tybost® (cobicistat tablets) drug product prior to the expiration of the ’374 Patent. PARTIES 2. Plaintiff Gilead Sciences, Inc. is a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 333 Lakeside Drive, Foster City, California 94404. 3. On information and belief, Defendant Mylan Pharmaceuticals Inc. is a corporation organized and existing under the laws of the State of West Virginia, having a principal place of Case 1:16-cv-00192-UNA Document 1 Filed 03/25/16 Page 2 of 11 PageID #: 2 business at 781 Chestnut Ridge Road, Morgantown, West Virginia 26505.
    [Show full text]